Mozambique bets on excellence in MDR-TB services to face the emergence of drug-resistant strains

Every year, the World commemorates the 24th of March, World Tuberculosis Day. This date constitutes an occasion to increase public awareness and understanding of one of the deadliest infectious killers in the world, tuberculosis, and its devastating impact on the health, social and economic of people around the world.

This year, as part of the National Commemorations, the Prime Minister of Mozambique, His Excellency Dr. Adriano Maleane, inaugurated the Centre of Excellence for the Management of Multidrug-resistant Tuberculosis that is located within the Machava General Hospital in Maputo Province, South of Mozambique. 

The Centre of Excellence for the Management of Multidrug-resistant Tuberculosis is an initiative conceived within the scope of the Southern Africa Tuberculosis and Health System Support funded by the World Bank to strengthen institutional capacity in the provision of services of excellence of Multidrug-resistant Tuberculosis; development and implementation of good clinical and programmatic practices, training and exchange of experience at national and international level, and intensification of research on tuberculosis1.

Mozambique's strategy for tuberculosis control is based on three pillars, namely: prevention and integrated patient-centred care; bold policies and support systems; and intensification of research and innovation. Through the implementation of this strategy, the country has documented noteworthy progress. In 2020, about 84% of people with tuberculosis were diagnosed and treated. For this feat, and for having achieved the global goal by reducing the number of deaths from tuberculosis by 54% compared to 2015 records, Mozambique was highlighted in the most recent global report on tuberculosis, published by the World Health Organization.

Despite the progress made, Mozambique ranks among TB high burden countries, as classified by the World Health Organization. The estimated incidence of Tuberculosis in Mozambique is 368/100,000, i.e., the disease currently affects about 115,000 Mozambicans2. The emergence of drug-resistant strains of Tuberculosis, the constraints children face in accessing tuberculosis services and the negative impact of the COVID-19 pandemic on the National Health Service represent a significant threat in the fight to eliminate this scourge.

Therefore, SATBHSSP is supporting interventions to strengthen case detection and improve treatment outcome, especially in high-risk groups, MDR-TB and occupational lung disease surveillance, and system strengthening. This support will potentially mitigate the impact of COVID-19 over health system and contribute to reducing the burden of the disease in Mozambique and in the region3.

References

1.        Mozambique Centre of Excellence infographic - Management of MDR TB | SATBHSS - Southern Africa Tuberculosis and Health Systems Support Project. https://www.satbhss.org/resources/infographics/mozambique-centre-excelle.... Accessed April 1, 2022.

2.        World Health Organization. Global Tuberculosis Report 2021. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/globa.... Published October 14, 2021. Accessed November 9, 2021.

3.        SATBHSSP. SATBHSS - Southern Africa Tuberculosis and Health Systems Support Project |. https://www.satbhss.org/. Accessed April 1, 2022.

 

 

 

No votes yet